Julie Fitzgerald to Follow-Up Studies
This is a "connection" page, showing publications Julie Fitzgerald has written about Follow-Up Studies.
Connection Strength
0.047
-
Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. J Clin Oncol. 2021 03 10; 39(8):920-930.
Score: 0.029
-
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013 Jun 27; 121(26):5154-7.
Score: 0.017